DEUTERONCOLOGY
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
DEUTERONCOLOGY
Industry:
Biotechnology Medical
Founded:
2020-01-01
Address:
Geel, Antwerpen, Belgium
Country:
Belgium
Website Url:
http://www.deuteroncology.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Amazon Google Apps For Business GStatic Google Static Content Sectigo SSL Sectigo Domain SSL
Similar Organizations
Origin
Origin is a privately held, clinical-stage biotechnology company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company.
Investors List
Newton Biocapital
Newton Biocapital investment in Seed Round - DeuterOncology
Official Site Inspections
http://www.deuteroncology.com
- Host name: 82.29.157.13
- IP address: 82.29.157.13
- Location: Middlesbrough United Kingdom
- Latitude: 54.5746
- Longitude: -1.1927
- Timezone: Europe/London
- Postal: TS3
More informations about "DeuterOncology"
DeuterOncology - Crunchbase Company Profile
Organization. DeuterOncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ...See details»
DeuterOncology NV - LinkedIn
DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical …See details»
Deuteroncology Company Profile | Liège, Liege, Belgium
Find company research, competitor information, contact details & financial data for Deuteroncology of Liège, Liege. Get the latest business insights from Dun & Bradstreet.See details»
DeuterOncology - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead ... obfuscated. obfuscated. Newton …See details»
DeuterOncology Company Profile 2025: Valuation, Funding
DeuterOncology General Information Description. Developer of MET inhibitors intended to optimize oncology treatments and outcomes. The company's lead compound is a dual MET …See details»
Product Pipeline - Deuteroncology
DeuterOncology’s lead product DO-2 is an improved MET kinase inhibitor, which is being developed as a potential ‘best in class’ targeted therapy for lung cancer. Learn more. …See details»
Press Release - Deuteroncology
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapy. Els Hubloux, partner …See details»
DeuterOncology - Contacts, Employees, Board Members, Advisors …
DeuterOncology is a preclinical-stage biotech company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales ... Experience the new Crunchbase, powered by AI . Organization. …See details»
DeuterOncology - EU-Startups
DeuterOncology NV was founded in September 2020 by Dr Timothy Perera in Flanders, Belgium. Developer of MET inhibitors intended to optimize oncology treatments and outcomes. The …See details»
DeuterOncology - Products, Competitors, Financials, Employees ...
Funding round-up: Cellaïon, Ferronova, AI Medical Technology, Vedi, DeuterOncology. Jan 30, 2023. Belgium: DeuterOncology, a clinical-stage drug development company, has closed its …See details»
DeuterOncology closes… | Newton Biocapital - Life Sciences …
DeuterOncology closes €5.65M Series A financing round - Belgian biotech company will use funding to start first-in-human clinical study for lead drug candidate in lung cancer. Liege, …See details»
Belgian biotech companies DeuterOncology and Radiomics …
“We are very pleased to establish this local collaboration with DeuterOncology and to be part of such a ground-breaking trial which could have global implications. Optimizing decision making …See details»
DeuterOncology Company Information - Funding, Investors, and …
The company DeuterOncology has raised a total of $6.11m in funding over 1 rounds. Key Insights: Series A: $6.11m; 2025. DeuterOncology Series A (2023, $6M) $6.11m. Similar …See details»
DO-2 – Deuteroncology
DeuterOncology’s lead product DO-2 is an improved MET kinase inhibitor, which is being developed as a potential ‘best in class’ targeted therapy for lung cancer. The metabolically …See details»
Life Sciences Investments - Newton Biocapital
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced …See details»
DeuterOncology closes €5.65M Series A financing round
Liege, Belgium, January 19, 2023 – DeuterOncology, a clinical-stage drug development company, today announces the closing of its €5.65 million ($6.1M) Series A financing, with participation …See details»
DeuterOncology closes €5.65M Series A financing round
DeuterOncology is a clinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. The company has …See details»
Belgian biotech companies DeuterOncology and Radiomics …
DeuterOncology has initiated a phase I clinical study to validate DO-2 as a best-in-class MET kinase inhibitor as suggested by the strong preclinical data package. Based in Liège, the …See details»
Residence time of DO-2, a novel deuterated MET kinase inhibitor …
[email protected] Disclosures: Timothy Perera is the founder and CEO of DeuterOncologyand is a share and stock option holder Frank Becker is founder and CEO of …See details»